Evidence map›Paper›PMID 30972193›Full record

ArticleAmerican journal of translational research2019

Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta.

Renuka P Limgala, Tabitha Jennelle, Matthew Plassmeyer, Michel Boutin, Pamela Lavoie, Mona Abaoui, Christiane Auray-Blais, Khan Nedd, Oral Alpan, Ozlem Goker-Alpan

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Renuka P LimgalaLysosomal and Rare Disorders Research and Treatment Center (LDRTC) Fairfax, VA 22030, USA.
Tabitha JennelleLysosomal and Rare Disorders Research and Treatment Center (LDRTC) Fairfax, VA 22030, USA.
Matthew PlassmeyerAmerimmune, O & O Alpan, LLC Fairfax, VA 22030, USA.
Michel BoutinDivision of Medical Genetics, Department of Pediatrics, Université de Sherbrooke Sherbrooke, Quebec, Canada.
Pamela LavoieDivision of Medical Genetics, Department of Pediatrics, Université de Sherbrooke Sherbrooke, Quebec, Canada.
Mona AbaouiDivision of Medical Genetics, Department of Pediatrics, Université de Sherbrooke Sherbrooke, Quebec, Canada.
Christiane Auray-BlaisDivision of Medical Genetics, Department of Pediatrics, Université de Sherbrooke Sherbrooke, Quebec, Canada.
Khan NeddInfusion Associates Grand Rapids, MI 49525, USA.
Oral AlpanAmerimmune, O & O Alpan, LLC Fairfax, VA 22030, USA.
Ozlem Goker-AlpanLysosomal and Rare Disorders Research and Treatment Center (LDRTC) Fairfax, VA 22030, USA.
Université de Sherbrooke · CALysosomal and Rare Disorders Research and Treatment Center · USO&O Alpan (United States) · USInfusion Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fabry disease (FD) is a rare X-linked genetic disorder caused by mutations in the

Indexed as

agalsidase alfaagalsidase betaenzyme replacement therapyFabry diseaseimmune alterationsimmune cellslyso-Gb3

Identifiers

PMID30972193
PMCPMC6456521
OpenAlexW2980479341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.